跳至主要内容
临床试验/NCT06019091
NCT06019091招募中不适用

Optimal Frequency Used in Transcutaneous Electrical Nerve Stimulation (TENS) for Treating Pelvic Pain in Adults

Albany Medical College2 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2022年7月20日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
75
试验地点
2
主要终点
Percent change in VAS and GUPI pain questionnaires from baseline to after two weeks of therapy.

研究概览

简要总结

TENS (transcutaneous electrical nerve stimulation) is accepted as a standard treatment for chronic pelvic pain, but the best settings to recommend, including frequency of stimulation, have not been defined to date. This study aims to find the optimal frequency, also known as cycles per second or Hertz (Hz) for treating chronic pelvic pain using non-invasive skin-level electrical nerve stimulation. The investigators will see how people respond to (20Hz, 50Hz or 100Hz). The study will have a two week control period (one week that looks back retrospectively at the week prior and another week looking prospectively at the patient symptoms) with no TENS unit and the participants normal standard of care treatments. This will be followed by 2 weeks of active TENS treatment for 30 minutes a day at the most painful time of day for the participant. The participant will also be allowed to extend their trial to study for durability for up to 3 additional months after the initial study. Participants will be asked to fill out a VAS (visual analog scale), GUPI (genitourinary pain index) and TENS usage log weekly.

详细描述

Adults ages 18-90 years old who have first been given the standard of care therapy according to the AUA/EUA guidelines depending on their specific pain modality, first line treatments based on suspected etiology (for example pelvic floor physical therapy for high tone pelvic floor muscle dysfunction or amitriptyline for interstitial cystitis) without success will be defined as refractory. Participants who have plateaued on their response to current intervention strategies will be offered the TENS unit as an adjunct.

Participation will be offered by mail or in person. If by mail, the investigators will send the consent with the letter and questionnaires asking participants to call or bring the material if they would like to enroll. If the investigators speak to the subject over the phone, the investigators will discuss the study as comprehensively as if they were in the clinic. This will include explaining the concept of the TENS unit, the study itself, and clarifying any questions the participant has. Subsequently if they are interested in the study, the investigators will ask them to sign the consent and return it to us via mail or email.

Those whose pain symptomatology is above a threshold and who choose TENS therapy will be included in the study. The participants will be randomized into three groups of 25 participants each. The randomization will occur in blocks so that if the investigators need to terminate the study early there will be an equal number of participants in each group. The size of the blocks will also be kept secret for allocation concealment purposes. The randomization will be stratified by gender so that there is an equal number of participants from each gender in each group, reducing potential for gender as a confounding variable. Group 1 will be the low frequency set at 20 Hz. Group 2 will be the medium frequency set at 50 Hz. Group 3 will be the high frequency set 100 Hz. There is no sham group in this study as it has previously been found that posterior tibial TENS is effective and lasting. As such, all participants will be treated as a matter of routine medical care for pelvic pain. The investigators will use a fixed pulse width of 200 microseconds (uS), with continuous rather than biphasic stimulation. The investigators will aim to recruit 25 participants per group for a total of 75 participants.

Study Procedures

Screening Day 7/ Week 1 (in clinic or virtual): The first data points (Day 0) will take place in the clinic during the participant's routine visit or at the time of the participant's phone call seeking participation. If during a phone call seeking participation, this will be considered a study phone call, not a billable visit. The participant will fill out the VAS and GUPI. The participants will be taught how to fill out the pain assessment questionnaires (the VAS and GUPI, validated tools for measuring genitourinary pain and symptoms respectively). This can be done via paper to be brought into the office at their next checkup or via an emailed link through Qualtrics and uploaded to a spreadsheet in a protected AMC OneDrive. The baseline pain logs will be reviewed for sufficient severity of pain episodes and the participant will be randomized into the study if their pain is above the designated threshold: participants who record a pain scale of 4 or higher on any of the VAS scores or QOL score of 3 or higher on the GUPI question #9 will be eligible for the TENS study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

盲法说明

There will be single blinding. Study participants/caretakers will not know which frequency has been assigned.

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Presenting with chronic pelvic pain (chronic/persistent pain that has been continuous or recurrent for at least three months (in accordance with EAU Guidelines).
  • Unsuccessful initial interventions based on initial assessments
  • Ability to provide informed consent and complete study requirements
  • Ability to complete a comprehensive history (including with an interpreter)

排除标准

  • Participants who have previously tried a new pharmacologic treatment for pelvic pain, neuromodulation or other alternative therapy for urologic disorders within the past 30 days
  • Inability to work a TENS unit
  • Any contraindications to usage of a TENS unit (pacemaker or other implantable device, lymphedema, pregnancy, malignancy, bleeding or clotting disorders, unhealthy tissue, seizure disorders, impaired cognition)
  • Any history of electrophysiologic heart disease or complications
  • Source of pain being an obvious anatomic issue requiring alternative treatment - for example urethral diverticulum, distal ureteric stone.
  • Participant who is pregnant
  • Participant with adhesive allergy either reported by the participant or upon chart review

结局指标

主要结局

Percent change in VAS and GUPI pain questionnaires from baseline to after two weeks of therapy.

时间窗: Three weeks

The primary objective of the study is to compare the three TENS treatment groups after two weeks of active treatment, with respect to: The change in VAS and GUPI pain questionnaires from baseline to after two weeks of therapy.

次要结局

  • Time dependent changes in GUPI questionnaire scores across the three TENS treatment groups(Three Weeks)
  • VAS questionnaire score comparison across the three TENS treatment groups(Three Weeks)
  • Time dependent changes in VAS questionnaire scores across the three TENS treatment groups(Three Weeks)
  • GUPI questionnaire score comparison across the three TENS treatment groups(Three Weeks)
  • Durability in optional extension phase of study(Three Months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Elise De

Principal Investigator

Albany Medical College

研究点 (2)

Loading locations...

相似试验